Management Team

Dr. Clemow has more than 25 years of experience in the development and management of orthopaedic devices. Most recently he was President and CEO of Nexgen Spine Inc. and before that Gelifex Inc. and Minimally Invasive Surgical Technologies, Inc. Previously, Dr. Clemow had 20 years of senior management experience at Johnson & Johnson including Vice President of Worldwide Business Development for both Ethicon EndoSurgery and Johnson & Johnson Professional. He holds a PhD from the University of Surrey, UK and an MBA from Columbia University

Prof. Seliktar brings 14 years of biomaterials and tissue engineering research experience in American, European, and Israeli Academic Institutions. Prior to joining the Biomedical Engineering Department at the Technion, Prof. Seliktar was an N.S.F. International Postdoctoral Research Fellow in the Department of Materials at the Swiss Federal Institute of Technology, Zurich, Switzerland (ETH). Prof. Seliktar holds a Bachelor’s degree in Mechanical Engineering from Drexel University (Summa Cum Laude), Philadelphia, PA, and a Master’s degree in Mechanical Engineering and a Ph.D. in Biomedical Engineering from the Georgia Institute of Technology, Atlanta, Georgia, USA.

Ms. Ben-Zur brings over 12 years of experience in the medical device industry, holding positions in management, business and marketing in the United States and in Israel. Prior to joining Regentis, Livnat served as VP Business Development & Dir of Women’s Health Program at Galil Medical. Before that Ms. Ben-Zur served as a Director of Marketing of Medinol Ltd, and as Business director of Medical Technology group of Datamonitor Inc. She holds MBA in marketing and International Business from Tel Aviv University and Bachelor of Sciences, Biology from Tel Aviv University.

Dr. Peled is a senior orthopedic surgeon at the Rambam Medical Center, Haifa, Israel. He brings more than 12 years of practice in joint replacement and orthopedic trauma. Dr. Peled earned his medical degree at the Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology (graduated with honor).

Dr. Wechsler brings over 12 years of experience in research and development in the biotechnology industry holding a variety of managerial positions with increasing role. Prior to joining Regentis, Dr. Wechsler served as a CTO of Procore LTD and before that a CTO of Prochon Biotech, both in the regenerative medicine and biomaterials fields. Before that Dr. Wechsler was a Director of Projects in QBI (presently Quark Pharma). He holds a B.Sc. degree in Biochemistry from McGill University, Montreal, and M.Sc. and PhD degrees in Life Sciences from the Weizmann Institute of Science.